Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$COCP is screaming for the top for the second session in a row after announcing a COVID-19 therapeutic development update. https://cnafinance.com/cocrystal-pharma-cocp-stock-rockets-on-covid-19-news/
*W* formation wit long handle [-chart]www.stockscores.com/chart.asp?TickerSymbol=COCP&TimeRange=15&Interval=30&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=20&avgType2=None&movAvg2=&Indicator1=RSI&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
$COCP CASH COW, $31.781M Cash Reading DD & Theory NEWS RELEASE 3-AUG-2020 New published study from K-State virologists identifies potential COVID-19 treatment
KANSAS STATE UNIVERSITY
https://www.cocrystalpharma.com/
update 04-22-21
New peer reviews of COVID-19 preprints from the MIT Press journal RAPID REVIEWS COVID-19
THE MIT PRESS
https://www.eurekalert.org/pub_releases/2020-09/tmp-npr090420.php
===============================================================
https://www.eurekalert.org/pub_releases/2020-08/ksu-nps080320.php
[-chart]media.eurekalert.org/multimedia_prod/pub/web/239228_web.jpg[/chart]
MANHATTAN, KANSAS -- Yunjeong Kim and Kyeong-Ok "KC" Chang,
virologists in the College of Veterinary Medicine at Kansas State University,
have published a study showing a possible therapeutic
treatment for COVID-19.
Pathogenic coronaviruses are a major threat to global public health,
as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV;
Middle East respiratory syndrome coronavirus, known as MERS-CoV;
and the newly emerged SARS-CoV-2, the virus that causes COVID-19 infection.
The study, "3C-like protease inhibitors block coronavirus replication
in vitro and improve survival in MERS-CoV-infected mice,"
appears in the Aug. 3 issue of the prestigious medical journal Science Translational Medicine.
It reveals how small molecule protease inhibitors show potency against human coronaviruses.
These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
"Vaccine developments and treatments are the biggest targets in
COVID-19 research, and treatment is really key,"
said Chang, professor of diagnostic medicine and pathobiology.
"This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target."
The study demonstrates that this series of optimized coronavirus
3CLpro inhibitors blocked replication of the human coronaviruses
MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS.
These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim have been using National Institutes of Health grants
to develop antiviral drugs to treat MERS and human norovirus infections.
Their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
"The work that this group of collaborators has been doing on
antivirals and inhibitors for SARS and MERS at K-State for a number
of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics,"
said Peter K. Dorhout, vice president for research at K-State.
Co-collaborators on the research include teams lead by Bill Groutas
at Wichita State University,
Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
"Drs. Groutas,
Perlman and
Lovell brought decades of experience to our research team,"
Chang said.
"We would not have been able to come this far without important collaborations with our colleagues at other institutions."
"Getting things published right now is very important for the scientific community," Kim said. "I think we are adding valuable information to the antiviral field."
###
The new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. K-State Innovations Partners handles commercial technology licensing for the university.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy
of news releases posted to EurekAlert! by contributing institutions
or for the use of any information through the EurekAlert system.
Cocrystal Pharma Australian Patent Office Abstract Titled 'Inhibitors of hepatitis C virus polymerase'
3:25 pm ET April 8, 2021 (Benzinga) Print
http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2016235246#
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cocrystal Pharma Inc (COCP)
1.16 ? -0.05 (-4.13%)
Volume: 624,577 @04/16/21 7:58:32 PM EDT
Bid Ask Day's Range
1.15 2.73 1.12 - 1.23
COCP Detailed Quote
COCP monster payday if you were patient over the past year with this COVID-19 antiviral!
Incorrect assumption. This will be #1 sort after drug in the world!
The virus will be long gone and will have mutated a dozen times by time they come out with a drug. Technology, the science, AI and big data change radically year from year. When are these guys going topull the trigger and quit partnering and just deliver? At least the new floor is $1.40.
$COCP Covid-19 Collaboration will be worth the long wait!
Cocrystal Pharma Inc (COCP)
1.7 ? 0.02 (1.19%)
Volume: 1,178,387 @02/24/21 5:29:31 PM EST
Bid Ask Day's Range
1.67 1.7 1.6509 - 1.78
COCP Detailed Quote
Cocrystal Pharma Inc (COCP)
1.96 ? 0.05 (2.62%)
Volume: 1,410,068 @02/19/21 7:21:54 PM EST
Bid Ask Day's Range
1.93 1.98 1.88 - 1.97
COCP Detailed Quote
Oh it will happen now, probably will go to $50 now that I sold last week...good luck
COCP very close if your still here... this will be move for the ages
[-chart]www.stockscores.com/chart.asp?TickerSymbol=COCP&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
What the fuck is going on with this stock? Going no where
Cocrystal Pharma Inc (COCP)
2.17 ? 0.06 (2.84%)
Volume: 130,396 @01/25/21 8:33:09 AM EST
Bid Ask Day's Range
2.17 2.18 - - -
COCP Detailed Quote
Interesting to see what happens next
COVID ERADICATE INFLUENZA VIRUS, USELESS GDRUG
IT TOOK 6 TRADING HOURS TO SINK $COCP & MERCK $MRK DEAL WOW [BIG TIME SLEEPER HERE] $COCP
01-19-2021
up 57% Cocrystal Pharma Inc (COCP) 2.38 ? 0.87 (57.62%)
[ONLY 5 MESSAGES TODAY ?????]
$COCP Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide Licens...
January 19 2021 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses,
SARS-CoV-2 virus, hepatitis C viruses and noroviruses,
announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement,
and that Merck is now solely responsible for further development
of the influenza A/B antiviral compounds that were discovered using Cocrystal’s unique structure-based technologies and Nobel Prize-winning expertise.
“Through a highly productive relationship with Merck,
teams from both companies worked collaboratively to rapidly advance
the discovery and initial development of promising proprietary
influenza A/B antiviral compounds,” said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal.
“Under the agreement announced in January 2019, Merck had an option
for Cocrystal to perform up to 12 months of additional work if the initial two years of collaboration did not progress as expected.
We are pleased our collaboration achieved its goals within the
timeline and that there is no need for Merck to exercise the option.
As this program advances, Merck is now responsible for funding
continued development of the compounds.”
“Developing new, effective influenza antivirals represents a
significant unmet worldwide medical need and is integral to our infectious diseases R&D strategy,”
said Daria Hazuda, Ph.D., Vice President, Infectious Diseases Discovery, Merck Research Laboratories and Chief Scientific Officer, Merck Exploratory Science Center.
“We are pleased with the progress under our collaboration with
Cocrystal and look forward to further development of the antiviral agents in the influenza A/B program at Merck.”
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that
target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses, and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
For further information about Cocrystal, please visit http://www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the further development of the influenza A/B compounds and the future commercialization of the compounds. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the results of Merck’s further research, products developed by competitors and internal issues related to Merck. Further information on our risk factors is contained in our filings with the SEC, including our Prospectus Supplement dated August 26, 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
# # #
Primary Logo
$COCP it is possible to awake wit ah buyout buyer pre-market trading
$COCP maybe @ least $10 January 19, 2021 12:18 pm ET Why Cocrystal Pharma, Precision BioScience Are Trading Higher Today
Benzinga
9:16 am ET
*Cocrystal Pharma shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds.
Benzinga
8:02 am ET
*Cocrystal Pharma Reports Completed All Research Obligations Under Merck Exclusive Global License, Collab Deal; Merck Is Solely Responsible For Further Development Of Influenza A/B Antiviral Compounds
Benzinga
This is going to be a serious run if the Bulls show up
Shorts are screwed..holding for tomorrow PM
COCP COVID-19 the steep climb begins in January if...
you are still in this soon to be monster biotech in the making!
[-chart]www.stockscores.com/chart.asp?TickerSymbol=COCP&TimeRange=180&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
WKLY
DOESN'T FIT DA GLOVE FOR WHAT COCP HAS IN DA PIPELINE !!!!!
Everyday this stock is down why?
$CAPR from Reuters.[ highly infectious coronavirus variant B.1.1.7]
Shortly after Biden’s remarks,
Colorado Governor Jared Polis said his state had discovered the nation’s first
known case of the highly infectious coronavirus variant B.1.1.7,
which was originally documented in the United Kingdom. Scientists there believe the variant is more contagious than other previously identified
strains of the SAR-CoV-2 variant but no more severe in the symptoms it causes.
It has also been detected in several European countries,
as well as in
Canada,
Australia,
India,
South Korea and
Japan,
among others.
Polis said in a statement the infected patient was a man in his 20s
with no recent travel history who is currently in isolation in Elbert County,
a semi-rural area on the outskirts of the greater Denver metropolitan area.
Lol, I threatened to buy back in and this stock dropped! Looks like COCP has been partnered with Merck but no mention of COCP’s drug yet. I ran across this recent headline where Merck has another couple of dogs in the therapy fight.
https://ih.advfn.com/stock-market/NYSE/merck-MRK/stock-news/83971580/merck-signs-supply-agreement-with-u-s-government
Wow what gives? HF’s swapping spit? Amazing!
$COCP READING YOUR REPORE' ON DRUG EFFECTIVENESS [Cocrystal Pharma Inc
will be releasing the compound molecules used to develop drug(s) to treat the Corona Virus this month at the end of the year or sooner before or after Christmas, but before New Year's.
I hope this time the company will use a professional to read their press release so this stock can soar like many other antiviral stocks.
Dr Gary Wilcox Kansas State University Research Foundation will have something great to celebrate after they released the leading compound molecules used to develop the inhibitors to treat the Covid-19 disease.
reading pre-market upticks 12-24-2020 to 'tredenwater2' on 'Cocrystal Pharma Inc. (COCP)'
[Theres no way they would release news going into Covid vaccine roll out but it does make you wonder how relevant the hundreds of millions if not billions of dollars that were spent on the vaccine would be if this tiny little company comes out with a drug that effectively nullifies the need to get a vaccine shot. Talk about a fake stock market moon shot! Early next year is my guess!]
OAN vaccine related I could not help but marvel yesterday as I sat and wondered when Gavin Newsome was finally going shut his mouth and leave that doc alone so he could administer the vaccine doses to eagerly waiting patients. Such a dweeb. Anything to have the camera pointed on him and get recognition for something he played absolutely no part in whatsoever. Did everyone see how fast that 3 state “vaccine advisory panel” of 17 peolle approved the use....? Lol just what we need, a bigger bureaucracy to tell those of us, who are so inept and incapable of thinking for ourselves, when they can or cant receive an FDA approved vaccine. CA needs to can pretty private party lockdown boy GN!
COCP Bid: 1.86 Ask: 1.92 Last: 1.88 Chg ($): 0.38 Vol: 125.30K
Anyone else up right now whiting the current price? It’s between 1.88 - 1.90
Theres no way they would release news going into Covid vaccine roll out but it does make you wonder how relevant the hundreds of millions if not billions of dollars that were spent on the vaccine would be if this tiny little company comes out with a drug that effectively nullifies the need to get a vaccine shot. Talk about a fake stock market moon shot! Early next year is my guess!
OAN vaccine related I could not help but marvel yesterday as I sat and wondered when Gavin Newsome was finally going shut his mouth and leave that doc alone so he could administer the vaccine doses to eagerly waiting patients. Such a dweeb. Anything to have the camera pointed on him and get recognition for something he played absolutely no part in whatsoever. Did everyone see how fast that 3 state “vaccine advisory panel” of 17 peolle approved the use....? Lol just what we need, a bigger bureaucracy to tell those of us, who are so inept and incapable of thinking for ourselves, when they can or cant receive an FDA approved vaccine. CA needs to can pretty private party lockdown boy GN!
Followers
|
103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3011
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators |
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses,
influenza viruses, and noroviruses.. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated
in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and
collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the
treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program
to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents.
These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics
that are safe, effective and convenient to administer.
Our technology provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide SAR.
This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement.
For any given viral disease, there are different subtypes of viruses that cause the disease. For example, there are six different subtypes of virus that cause hepatitis C.
In hepatitis C, these subtypes are termed "genotypes." Each hepatitis C genotype is common in some parts of the world and rare in others.
Our technology allows us to develop drug candidates that are effective against all subtypes of a given virus. The drug candidate is called broad spectrum.
Viral resistance is a major obstacle to developing effective antiviral therapies that target viral molecules. Viruses reproduce rapidly and in enormous quantities.
During reproduction, random variations in viral molecules called mutations spontaneously develop. If such a mutation occurs in a viral molecule that is targeted
by an antiviral therapy that therapy may no longer be effective against the mutated virus. These mutated or "resistant viruses" can freely infect and multiply even
in individuals who have received treatment. In some cases, resistant virus strains may even predominate. For example, in the 2009 swine influenza pandemic,
the predominant strain was resistant to the best available therapies.
To overcome this obstacle, we identify and target critical components of viral replication enzymes that are crucial to the function of the enzyme and sensitive to change.
Any mutation in these critical enzyme components is likely to inactivate the enzyme and, in turn render the virus incapable of replicating. We test the effectiveness of
our compounds against potential viral mutations and select compounds with the highest barrier to resistance.
Patients at risk for suffering from many viral infections have few effective antiviral treatments from which to choose. Furthermore, some available treatment options have characteristics that limit their market potential. They are either priced too high, poorly tolerated, inconvenient to administer, ineffective against some viral subtypes or prone to emergence of resistance.
Our technology is based on the work of our Chief Scientist and Chairman of our Scientific Advisory Board, Dr. Roger Kornberg, and Dr. Raymond Schinazi.
Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to visualize a replication enzyme called RNA polymerase in action.
Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated three dimensional pictures
similar to the one on the left of RNA being transcribed by an RNA polymerase.
Dr. Schinazi is a world-class expert in discovering novel nucleoside therapeutics. He co-founded several successful antiviral companies including
Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.
We are leveraging both Dr. Kornberg's and Dr. Schinazi's expertise in these methods to identify and develop new antiviral compounds.
Using these methods, our scientists are able to:
Influenza is a severe respiratory illness caused by either the influenza A or B virus that results in outbreaks of disease mainly during the winter months.
Currently approved antiviral treatments for influenza are partially effective and prone to viral resistance. Strains of flu virus that are resistant to approved treatments,
osteltamivir (Tamiflu™), zanamavir (Relenza™) and Xofluza have appeared and in some cases are predominant.
For example, the predominant strain of the 2009 swine influenza pandemic was resistant to Tamiflu™.
These drugs target one of two viral proteins, hemagglutinin or neuraminidase, neither of which is highly conserved between viral strains.
In fact, different influenza virus strains such as H1N1 and H5N1 are named by their respective differences in hemagglutinin (H) and neuraminidase (N) proteins.
The ability of the influenza virus to produce viable variants of these two proteins is the key to its ability to develop resistance.
To learn more about influenza, please visit the information page at the Center for Disease Control and Prevention (CDC).
References: https://www.cdc.gov/flu/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |